Evidence map›Paper›PMID 37266092›Full record

ReviewIndian dermatology online journal

Nail Society of India (NSI) Recommendations for Pharmacologic Therapy of Onychomycosis.

Khushbu Mahajan, Chander Grover, Vineet Relhan, Sushil Tahiliani, Archana Singal, M Manjunath Shenoy, Deepak Jakhar

Open access · diamondAbstract readReview
In one paragraph

Review in Indian dermatology online journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Antifungal pulse therapy for onychomycosis: a narrative review.European journal of clinical pharmacology · 2026
    Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Khushbu MahajanConsultant Dermatologist, Mahajan Skin Centre and Kubba Skin Clinic, Delhi, India.
Chander GroverDepartment of Dermatology and STD, University College of Medical Sciences and GTB Hospital, Delhi, India.
Vineet RelhanDepartment of Dermatology and STD, Maulana Azad Medical College and LN Hospital, Delhi, India.
Sushil TahilianiConsultant Dermatologist, Hinduja Hospital and MRC, Dr Tahiliani's Skin Clinic, Mumbai, Maharashtra, India.
Archana SingalDepartment of Dermatology and STD, University College of Medical Sciences and GTB Hospital, Delhi, India.
M Manjunath ShenoyDepartment of Dermatology, Venereology and Leprosy, Yenepoya Medical College, Yenepoya (Deemed to be University), Mangalore, Karnataka, India.
Deepak JakharConsultant Dermatologist, Dermosphere Skin Clinic, Delhi, India.
Guru Teg Bahadur Hospital · INMaulana Azad Medical College · INUniversity College of Medical Sciences · INYenepoya University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Onychomycosis (OM) is the commonest cause of dystrophic nails, responsible for upto 50% of cases. Apart from significantly damaging the nails, quality of life, and self-image of the sufferer, it also acts as a reservoir of fungal infections carrying important implications for emerging recalcitrant dermatophytoses. Treatment of OM is based on guidelines released almost a decade back, in addition to published literature and personal preferences. Hence, an expert group of nail society of India (NSI) worked towards drafting these guidelines aimed at compiling recommendations for pharmacologic treatment of OM, based on scientific evidence, along with practical experience. The group did an extensive analysis of available English language literature on OM published during the period 2014-2022. The evidence compiled was graded and discussed to derive consensus recommendations for practice. Special focus was placed on combination therapies and adjunct therapies, including experience of members, to improve treatment outcomes.

Indexed as

Antifungalgrade of recommendationitraconazolelevel of evidenceonychomycosisterbinafinetinea unguium

Identifiers

PMID37266092
PMCPMC10231711
OpenAlexW4367295054

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.